{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020152","form_type":"8-K","ticker":"NORD","cik":"0001011060","company_name":"Nordicus Partners Corp","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.863565+00:00","generated_at":"2026-06-01T18:26:36.948993+00:00","sec_items":["1.01","2.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Nordicus acquires 95% of Orocidin A/S for $38M in stock, enters periodontitis market","bullets":["Acquired 525,597 Orocidin shares (95% stake) from 11 shareholders for 38M restricted common shares.","Consideration valued at $38M in an all-stock transaction; closed May 13, 2024.","Nordicus CEO Henrik Rouf and Director Henrik Keller join Orocidin's board of directors.","Orocidin is a clinical-stage biopharma developing QR-01 for periodontitis; global market estimated >$1.3B by 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020152","json":"https://secwatch.observer/filing/0001493152-24-020152.json","markdown":"https://secwatch.observer/filing/0001493152-24-020152.md","text":"https://secwatch.observer/filing/0001493152-24-020152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T18:26:36.948993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a791b2497fa5694819f95d7ed249234ccb058e82","claim":"Nordicus Partners Corp completed an acquisition involving certain shareholders of Orocidin A/S (closed 2024-05-13).","evidence_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"certain shareholders of Orocidin A/S"},{"label":"Closing","value":"2024-05-13"}]},{"claim_id":"3bae1550a36d41a793cc417d9a5674836ee45605","claim":"Nordicus Partners Corp entered into Stock Purchase and Sale Agreement with certain shareholders of Orocidin A/S (effective 2024-05-13).","evidence_excerpt":"On May 13, 2024, Nordicus Partners Corporation (the “Company”) and certain shareholders (the “Sellers”) of Orocidin A/S, a Danish stock corporation (“Orocidin”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"certain shareholders of Orocidin A/S"},{"label":"Effective","value":"2024-05-13"}]}],"comparable_filings":[{"accession":"0001738827-26-000023","ticker":"KLXE","company_name":"KLX Energy Services Holdings, Inc.","filed_at":"2026-06-02T21:14:16+00:00","headline":"KLX Energy acquires Wolfpack assets for $17M; also exchanges $2.19M notes for equity","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: ma_transaction, material_agreement","same SEC item: 1.01, 2.01, 3.02, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001738827-26-000023","json":"https://secwatch.observer/filing/0001738827-26-000023.json","markdown":"https://secwatch.observer/filing/0001738827-26-000023.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738827/000173882726000023/0001738827-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738827/000173882726000023/klxe-20260602.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","comparable_excerpt":"“Buyer”), the Company and, solely for purposes of Section 8.05 thereto, Stevie Cooper and Stewart Cooper (the “Purchase Agreement”). The purchase price for the Acquisition is $17.0 million, subject to customary post-closing adjustments and to be paid as follows: (i) on the Closing Date, the Buyer paid the Seller $14.0 million in cash; (ii) 180 days after the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1738827/000173882726000023/0001738827-26-000023-index.htm"}},{"accession":"0001104659-26-069515","ticker":"XRN","company_name":"Chiron Real Estate Inc.","filed_at":"2026-06-02T20:30:45+00:00","headline":"Chiron Real Estate closes $249M acquisition of two senior housing communities; issues $100M Series C preferred","event_type":"m_and_a","sec_items":["1.01","2.01","2.03","3.02","3.03","5.03","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: ma_transaction, material_agreement","same SEC item: 1.01, 2.01, 3.02, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069515","json":"https://secwatch.observer/filing/0001104659-26-069515.json","markdown":"https://secwatch.observer/filing/0001104659-26-069515.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926069515/0001104659-26-069515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926069515/tm2616685d1_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","comparable_excerpt":"On June 1, 2026, the Company, through one or more subsidiaries, closed on the acquisition of The Landing Alexandria (the “ Landing ”), a senior housing community located in Alexandria, Virginia for a purchase price of $130 million.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926069515/0001104659-26-069515-index.htm"}},{"accession":"0000107140-26-000034","ticker":"WLY","company_name":"JOHN WILEY & SONS, INC.","filed_at":"2026-06-02T12:30:39+00:00","headline":"Wiley acquires Emerald Publishing for $452M; adds ~500 journals, expected accretive in year one","event_type":"m_and_a","sec_items":["1.01","2.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: ma_transaction, material_agreement","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000107140-26-000034","json":"https://secwatch.observer/filing/0000107140-26-000034.json","markdown":"https://secwatch.observer/filing/0000107140-26-000034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/107140/000010714026000034/0000107140-26-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/107140/000010714026000034/jwa-20260601.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","comparable_excerpt":"pursuant to which Buyer acquired from the Seller all of the issued and outstanding equity securities of Emerald Holding (the \"Transaction\") in exchange for GBP £337.5 million (approximately $452 million)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/107140/000010714026000034/0000107140-26-000034-index.htm"}},{"accession":"0001193125-26-251758","ticker":"OCFC","company_name":"OCEANFIRST FINANCIAL CORP","filed_at":"2026-06-01T21:19:28+00:00","headline":"OceanFirst closes acquisition of Flushing Financial; issues shares to Warburg Pincus","event_type":"m_and_a","sec_items":["1.01","3.02","2.01","2.03","3.03","5.02","5.03","7.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 3.02, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251758","json":"https://secwatch.observer/filing/0001193125-26-251758.json","markdown":"https://secwatch.observer/filing/0001193125-26-251758.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1004702/000119312526251758/0001193125-26-251758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1004702/000119312526251758/d145829d8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","comparable_excerpt":"of Flushing (“ Flushing Common Stock ”) issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was converted into the right to receive 0.85 of a share (the “ Exchange Ratio ”) of common stock, par value $0.01 per share, of OceanFirst (“ OceanFirst Common Stock ” and such consideration, the “ Merger Consideration ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1004702/000119312526251758/0001193125-26-251758-index.htm"}},{"accession":"0001193125-26-251442","ticker":"RPAY","company_name":"Repay Holdings Corp","filed_at":"2026-06-01T20:14:04+00:00","headline":"REPAY closes $372M acquisition of KUBRA, funded with new $500M term loan","event_type":"m_and_a","sec_items":["1.01","2.01","1.02","9.01","2.03","7.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: ma_transaction, material_agreement","same SEC item: 1.01, 2.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251442","json":"https://secwatch.observer/filing/0001193125-26-251442.json","markdown":"https://secwatch.observer/filing/0001193125-26-251442.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720592/000119312526251442/0001193125-26-251442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720592/000119312526251442/rpay-20260601.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","comparable_excerpt":"KUBRA became an indirect wholly owned subsidiary of the Company. Pursuant to the Purchase Agreement, the aggregate cash purchase price for the Acquisition was approximately $372 million, subject to customary post-closing adjustments. The closing cash consideration was funded with a combination of cash on hand and borrowings under the Credit Agreement described","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720592/000119312526251442/0001193125-26-251442-index.htm"}},{"accession":"0001213900-26-061792","ticker":"OLOX","company_name":"OLENOX INDUSTRIES INC.","filed_at":"2026-05-28T12:30:18+00:00","headline":"Olenox acquires CS Digital for $30M upfront; launches gas-powered data center platform","event_type":"m_and_a","sec_items":["1.01","5.03","2.01","2.03","3.02","7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 3.02, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061792","json":"https://secwatch.observer/filing/0001213900-26-061792.json","markdown":"https://secwatch.observer/filing/0001213900-26-061792.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023994/000121390026061792/0001213900-26-061792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023994/000121390026061792/ea0292420-8k_olenox.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","comparable_excerpt":"of CS Digital (the “Acquisition”) on the same date. Aggregate Consideration. The aggregate\nconsideration payable by the Company under the Purchase Agreement consists of: (i) US$30,000,000 in upfront consideration, payable at\nclosing, comprised of (a) US$14,000,000 in newly issued shares of the Company’s Series D Preferred Stock, par value $1.00 per share\n(the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1023994/000121390026061792/0001213900-26-061792-index.htm"}},{"accession":"0001096906-26-000819","ticker":"HYEX","company_name":"HEALTHY EXTRACTS INC.","filed_at":"2026-05-18T19:25:15+00:00","headline":"Healthy Extracts Inc. acquires Adli Gummies Inc. for notes and equity","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","5.02","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 3.02, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-26-000819","json":"https://secwatch.observer/filing/0001096906-26-000819.json","markdown":"https://secwatch.observer/filing/0001096906-26-000819.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630176/000109690626000819/0001096906-26-000819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630176/000109690626000819/hyex-20260515_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","comparable_excerpt":"On May 15, 2026, we entered into an Acquisition Agreement (the “Acquisition Agreement”) with Adli Gummies Inc., an Ontario corporation which does business as Imaraïs Beauty (“Adli”), and its shareholders. Pursuant to the Acquisition Agreement, through our wholly-owned subsidiary Healthy Extracts Canada Inc., a British Columbia corporation (“HE Canada”), we acquired one-hundred percent (100%) of the outstanding membership interests of Adli, which became our wholly-owned subsidiary.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1630176/000109690626000819/0001096906-26-000819-index.htm"}},{"accession":"0001193125-26-228133","ticker":"QNCX","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-05-18T13:33:34+00:00","headline":"Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts","event_type":"m_and_a","sec_items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"materiality_score":1.0,"calibrated_materiality_score":1.0,"match_reasons":["same fact type: ma_transaction","same SEC item: 1.01, 2.01, 3.02, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-228133","json":"https://secwatch.observer/filing/0001193125-26-228133.json","markdown":"https://secwatch.observer/filing/0001193125-26-228133.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/0001193125-26-228133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/d109149d8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"the Company acquired the Orocidin Shares pursuant to the Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm","comparable_excerpt":"On May 18, 2026, the Company completed its acquisition of the Orphai Entities.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/0001193125-26-228133-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}